The present disclosure relates generally to methods of treating a respiratory tract infection in a subject by administering to the subject in need thereof a therapeutically effective amount of C-terminal fragments of growth hormone, including LAT8881, otherwise known as AOD9604, or LAT9991F, and pharmaceutically acceptable salts thereof.
The present disclosure relates generally to a method of screening for and identifying a ligand of a Lanthionine synthetase C-like protein (LANCL) and the use of the identified ligands for the treatment of conditions, including pain. Also disclosed herein is a method of treating a condition, including pain, comprising administering to a subject in need thereof a therapeutically effective amount of an agent that binds to Lanthionine synthetase C-like protein 1 (LANCL1), wherein the agent is not a peptide derived from human growth hormone, or from a non-human homologue thereof, and wherein the agent competes for binding to LANCL1 with a cyclic peptide comprising SEQ ID NO:1 (YLRIVQCRSVEGSCGF).
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/616 - Acide salicyliqueSes dérivés ayant le groupe hydroxyle en position 2 estérifié, p. ex. acide salicylsulfurique par des acides carboxyliques, p. ex. acide acétylsalicylique
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
3.
PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF
The present invention provides various peptide compositions capable of binding Lanthionine synthetase C-like protein (LanCL) that have analgesic, anti-inflammatory and anti-microbial properties.The compositions comprise a peptide formula (I): X1-X2-X3- X4-X5-X6, wherein X represents specific groups of amino acids, and the peptide is 3-20 amino acids in length, it does not comprise sequences CRSRPVESSC, CRSVEGSCG, or CRIIHNNNC and is not a linear peptide comprising the sequence EQLERALNSS.
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 5/09 - Tripeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
C07K 5/11 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
4.
PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF
1234566, wherein X represents specific groups of amino acids, and the peptide is 3-20 amino acids in length, it does not comprise sequences CRSRPVESSC, CRSVEGSCG, or CRIIHNNNC and is not a linear peptide comprising the sequence EQLERALNSS.
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 5/09 - Tripeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
C07K 5/11 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
Disclosed herein are methods and compositions for treating or preventing neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of prolactin, or a functional variant thereof, wherein the functional variant comprises a peptide of formula (I) or a pharmaceutically acceptable salt thereof: R1-C-R-I-X1-X2-X3-X4-N-C-R2 (I) (SEQ ID NO:1) wherein X1 is an amino acid residue selected from isoleucine (I) and valine (V); X2 is an amino acid residue selected from histidine (H) and tyrosine (Y); X3 is an amino acid residue selected from aspartic acid (D) and asparagine (N); X4 is an amino acid Nresidue selected from asparagine (N) and serine (S); R1 is selected from the group consisting of YLKLLK, LKLLK, KLLK, LLK, LL, K or R1 is absent; and R2 is G (glycine), or R2 is absent.
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present disclosure relates to the use of C-terminal fragments of human and non-human growth hormone, synthetic cyclic peptides and C-terminal fragments of human prolactin precursor for the treatment of migraine in a subject in need thereof.
The present disclosure relates generally to methods of treating a respiratory tract infection in a subject by administering to the subject in need thereof a therapeutically effective amount of C - terminal fragments of growth hormone, including LAT8881, otherwise known as AOD9604, or LAT9991F, and pharmaceutically acceptable salts thereof.
The present disclosure relates generally to methods of treating a respiratory tract infection in a subject by administering to the subject in need thereof a therapeutically effective amount of C - terminal fragments of growth hormone, including LAT8881, otherwise known as AOD9604, or LAT9991F, and pharmaceutically acceptable salts thereof.
The present disclosure relates generally to a method of screening for and identifying a ligand of a Lanthionine synthetase C-like protein (LANCL) and the use of the identified ligands for the treatment of conditions, including pain. Also disclosed herein is a method of treating a condition, including pain, comprising administering to a subject in need thereof a therapeutically effective amount of an agent that binds to Lanthionine synthetase C-like protein 1 (LANCL1), wherein the agent is not a peptide derived from human growth hormone, or from a non-human homologue thereof, and wherein the agent competes for binding to LANCL1 with a cyclic peptide comprising SEQ ID NO:1 (YLRIVQCRSVEGSCGF).
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
10.
CYCLIC PEPTIDE RECEPTOR LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF
The present disclosure relates generally to a method of screening for and identifying a ligand of a Lanthionine synthetase C-like protein (LANCL) and the use of the identified ligands for the treatment of conditions, including pain. Also disclosed herein is a method of treating a condition, including pain, comprising administering to a subject in need thereof a therapeutically effective amount of an agent that binds to Lanthionine synthetase C-like protein 1 (LANCL1), wherein the agent is not a peptide derived from human growth hormone, or from a non-human homologue thereof, and wherein the agent competes for binding to LANCL1 with a cyclic peptide comprising SEQ ID NO:1 (YLRIVQCRSVEGSCGF).
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
2 is absent; and wherein the peptide of formula (I), or the pharmaceutically acceptable salt thereof, is a cyclic peptide formed by a disulphide bond between the two cysteine residues.
Disclosed herein are methods and compositions for treating or preventing neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of prolactin, or a functional variant thereof, wherein the functional variant comprises a peptide of formula (I) or a pharmaceutically acceptable salt thereof: R112344-N-C-R212344 is an amino acid residue selected from asparagine (N) and serine (S); R1is selected from the group consisting of YLKLLK, LKLLK, KLLK, LLK, LL, K or R1is absent; and R2is G (glycine), or R2 is absent.
The present disclosure relates to the use of C-terminal fragments of human and non-human growth hormone, synthetic cyclic peptides and C-terminal fragments of human prolactin precursor for the treatment of migraine in a subject in need thereof.
The present disclosure is directed to a peptide of formula (I), or a pharmaceutically acceptable salt thereof, and uses thereof: R1-C-R-X1-X2 -P-X3-X4-X5-X6-C-R2 (I) wherein X1, X3, X5, and X6 is an amino acid residue selected from the group consisting of serine, alanine, valine, leucine, isoleucine and glycine; X2 is alanine, arginine or lysine; X4 is glutamic acid or aspartic acid; R1 is selected from the group consisting of S, HS, GHS, PGHS, APGHS, EAPGHS, SEAPGHS, SSEAPGHS, PSSEAPGHS, DPSSEAPGHS and IDPSSEAPGHS, or R1 is absent; and R2 is selected from the group consisting of S, SS, SSK, SSKF, SSKFS, SSKFSW, SSKFSWD, SSKFSWDE, SSKFSWDEY, SSKFSWDEYE, SSKFSWDEYEQ, SSKFSWDEYEQY, SSKFSWDEYEQYK, SSKFSWDEYEQYKK, SSKFSWDEYEQYKKE, or R2 is absent; and wherein the peptide of formula (I), or the pharmaceutically acceptable salt thereof, is a cyclic peptide formed by a disulphide bond between the two cysteine residues.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
The present disclosure is directed to a peptide of formula (I), or a pharmaceutically acceptable salt thereof, and uses thereof: R1-C-R-X1-X2-P-X3-X4-X5-X6-C-R2(I) wherein X1, X3, X5, and X6is an amino acid residue selected from the group consisting of serine, alanine, valine, leucine, isoleucine and glycine; X2is alanine, arginine or lysine; X4is glutamic acid or aspartic acid; R1is selected from the group consisting of S, HS, GHS, PGHS, APGHS, EAPGHS, SEAPGHS, SSEAPGHS, PSSEAPGHS, DPSSEAPGHS and IDPSSEAPGHS, or R1is absent; and R2is selected from the group consisting of S, SS, SSK, SSKF, SSKFS, SSKFSW, SSKFSWD, SSKFSWDE, SSKFSWDEY, SSKFSWDEYE, SSKFSWDEYEQ, SSKFSWDEYEQY, SSKFSWDEYEQYK, SSKFSWDEYEQYKK, SSKFSWDEYEQYKKE, or R2 is absent; and wherein the peptide of formula (I), or the pharmaceutically acceptable salt thereof, is a cyclic peptide formed by a disulphide bond between the two cysteine residues.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
16.
HUMAN GROWTH HORMONE-DERIVED PEPTIDES, AND NON-HUMAN VARIANTS THEREOF, FOR TREATING NEUROPATHIC PAIN
A method of treating neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of a peptide of formula (I) or (II), or a pharmaceutically acceptable salt thereof: R1-CRSVEGSCG-R2 (I) (SEQ ID NO:1) wherein R1 is selected from the group consisting of YLRIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R is absent; and R2 is F (phenylalanine) or R2 is absent. R1-CRRFVESSC-R2 (II) (SEQ ID NO:6) wherein R1 is selected from the group consisting of YLRVMIK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and R2 is selected from the group consisting of A (alanine) and AF (alanine-phenylalanine), or R2 is absent.
A method of treating neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of a peptide of formula (I) or (II), or a pharmaceutically acceptable salt thereof: R1-CRSVEGSCG-R2 (I) (SEQ ID NO:1) wherein R1 is selected from the group consisting of YLRIVQ, LRIVQ, RIVQ, IVQ, VQ, and Q, or R is absent; and R2 is F (phenylalanine) or R2 is absent. R1-CRRFVESSC-R2 (II) (SEQ ID NO:6) wherein R1 is selected from the group consisting of YLRVMIK, LRVMK, RVMK, VMK, MK, and K, or R1 is absent; and R2 is selected from the group consisting of A (alanine) and AF (alanine-phenylalanine), or R2 is absent.
brevets
